AUROPHARMA.NSAUROPHARMA.NSNSE
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+6.3%
5Y CAGR+7.8%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+6.3%/yr
vs +15.6%/yr prior
5Y CAGR
+7.8%/yr
Consistent
Acceleration
-9.3pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
1.5x
Solid growth
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$62.39B+12.1%
2024$55.66B+8.9%
2023$51.09B-1.7%
2022$52.00B+0.3%
2021$51.82B+20.6%
2020$42.95B+19.1%
2019$36.07B+23.9%
2018$29.11B+21.8%
2017$23.90B+18.6%
2016$20.16B-